Results 1 to 10 of about 718,096 (263)

Paraquat ingestion in an adult with cystic fibrosis (CF): Diagnostic and management dilemmas

Respirology Case Reports, 2023
N,N'‐dimethyl‐4,4'bipyridinium dichloride (Paraquat) is a potent herbicide used widely in agriculture. We report the effects of an ingestion of paraquat by a 28 year old male with cystic fibrosis and the diagnostic and management challenges this posed in
Ieuan E. S. Evans, Shanal Kumar, Megan France, Daniel Smith, Philip Masel, George Tay, Daniel Henderson, Scott C. Bell, David Reid   +8 more
doaj   +1 more source

Malignancies in patients with cystic fibrosis: a case series

Journal of Medical Case Reports, 2022
Background Previous reports have shown an increased number of colorectal cancers in patients with cystic fibrosis. We assessed the database of our cystic fibrosis center to identify patients with all kinds of cancer retrospectively. All patients visiting
Dorothea Appelt, Teresa Fuchs, Gratiana Steinkamp, Helmut Ellemunter   +3 more
doaj   +1 more source

Efficacy of the Simeox^® Airway Clearance Technology in the Homecare Treatment of Children with Clinically Stable Cystic Fibrosis: A Randomized Controlled Trial

Children, 2023
Background: Cystic fibrosis (CF) patients require regular airway clearance therapy (ACT). The aim of this study was to evaluate homecare therapeutic effects of a new ACT (Simeox®) added to the optimal standard of care, including home chest physiotherapy,
Dorota Sands, Katarzyna Walicka-Serzysko, Justyna Milczewska, Magdalena Postek, Natalia Jeneralska, Aleksandra Cichocka, Ewa Siedlecka, Urszula Borawska-Kowalczyk, Laurent Morin   +8 more
doaj   +1 more source

Virtual Peer Support for People With Cystic Fibrosis and Their Family Members: A Program Evaluation

Journal of Patient Experience, 2020
We sought to evaluate the feasibility, acceptability, and benefits of a virtual one-to-one peer support program for people with cystic fibrosis and their family members through a retrospective program evaluation.
Aimee Jeffrey MSN, Lauren Andracchio MPH, Meg Dvorak LCSW, Paula Lomas MAS, RN, CCRP, Beth Smith MD, Drucy Borowitz MD   +5 more
doaj   +1 more source

Research progress on multiple cell death pathways of podocytes in diabetic kidney disease

Molecular Medicine, 2023
Diabetic kidney disease (DKD) is the main cause of end-stage renal disease, and its clinical manifestations are progressive proteinuria, decreased glomerular filtration rate, and renal failure. The injury and death of glomerular podocytes are the keys to
Can Yang, Zhen Zhang, Jieting Liu, Peijian Chen, Jialing Li, Haiying Shu, Yanhui Chu, Luxin Li   +7 more
doaj   +1 more source

Clinical complications in children with false-negative results in cystic fibrosis newborn screening

Jornal de Pediatria, 2022
Objective: To present signs and symptoms and clinical course in cystic fibrosis patients with false-negative newborn screening (CF NBS). Materials and methods: All children presented in this paper were covered by CF NBS.
Katarzyna Zybert, Urszula Borawska-Kowalczyk, Lukasz Wozniacki, Malwina Dawidziuk, Mariusz Ołtarzewski, Dorota Sands   +5 more
doaj   +1 more source

Prokaryotic expression, purification and evaluation of anti-cardiac fibrosis activity of recombinant TGF-β latency associated peptide [PDF]

PeerJ, 2022
Background Cardiac fibrosis refers to the abnormal accumulation of extracellular matrix in the heart, which leads to the formation of cardiac scars. It causes systolic and diastolic dysfunction, and ultimately leads to cardiac dysfunction and arrhythmia.
Xudong Song, Yufei Qiu, Jiayi Shi, Luxin Li, Xiaohuan Yuan, Dan Wu, Yanhui Chu   +6 more
doaj   +2 more sources

Upregulation of a CFTR mRNA isoform has therapeutic potential for the treatment of 3′ CFTR PTC variants

Molecular Therapy: Nucleic Acids
Nonsense or premature termination codon (PTC) variants of the CFTR gene are pathogenic and found in ∼10% of North American people with cystic fibrosis.
Normand E. Allaire, Matthew S. Armstrong, Jae Seok Yoon, Mercy C. Walker, Priyanka Bhatt, Jan M. Harrington, Yi Cheng, Eric I. Wong, John E. Mahoney, Hillary C. Valley, Caitlin M. Macadino, Hermann J. Bihler, Andrey Y. Sivachenko, Calvin U. Cotton, John P. Carulli, Martin Mense   +15 more
doaj   +1 more source

Elevated sweat chloride test: is it always cystic fibrosis?

Italian Journal of Pediatrics, 2021
Background The sweat chloride test (ST) is the gold standard for cystic fibrosis (CF) diagnosis in symptomatic patients, within the newborn screening and in the follow-up of CF patients during molecular therapies.
C. Cimbalo, A. Tosco, V. Terlizzi, A. Sepe, A. Castaldo, L. Salvadori, V. Raia   +6 more
doaj   +1 more source

REAL‐world clinical effectiveness of ivacaftor therapy in the first 24 months in two infants with cystic fibrosis and different gating mutations—A case report

Clinical Case Reports, 2022
This study summarizes efficacy of ivacaftor treatment in 2 infants in a real‐world setting. A distinct decline of sweat chloride and lung clearance index plus increase in fecal elastase was seen. The results underline the early and sustainable effect and
Teresa Fuchs, Dorothea Appelt, Katharina Niedermayr, Helmut Ellemunter   +3 more
doaj   +1 more source